Fact CheckerSign in

NCT07726381Not yet recruiting

Relation Between Glycemic Control and Retinal Microvascular Changes in Diabetic Patients Using OCTA

Source: ClinicalTrials.gov · Last updated 24 Jul 2026

Brief summary (registry, in English)

An observational cross-sectional comparative study which will be conducted in the Department of Ophthalmology, Sohag University Hospital, Egypt to detect the relation between glycemic control and retinal microvascular changes in diabetic patients using OCTA

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
50 (estimated)
First submitted
20 Jul 2026
Start date
1 Aug 2026
Primary completion date
1 Feb 2027
Lead sponsor
Sohag University
NCT number
NCT07726381

What you commit to

  • Study type: Observational
  • Planned participants: 50
  • From 1 Aug 2026 to the primary completion date, 1 Feb 2027
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients who have had previous intravitreal injections or Laser treatment.
  • Patients who underwent previous vitreoretinal surgeries.

Other illness

  • Patients with recent history of undergoing cataract surgery.

Age

  • Patients with any other retinal vascular diseases (retinal vein occlusion, central serrous chorioretinopathy, age-related macular degeneration, etc).

Other

  • Media opacities affecting OCT imaging (corneal pathologies, dense cataracts, vitreous opacities, etc).
  • Patients with uncontrolled glaucoma or ocular inflammations (eg: vitritis).

Who the study is looking for

  • Diabetic patients with diabetic retinopathy with controlled and uncontrolled HbA1c

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.